Key Developments: JCL Bioassay Corp (2190.T)

2190.T on Tokyo Stock Exchange

459JPY
12:55am EST
Price Change (% chg)

¥13 (+2.91%)
Prev Close
¥446
Open
¥448
Day's High
¥460
Day's Low
¥448
Volume
11,800
Avg. Vol
19,905
52-wk High
¥657
52-wk Low
¥360

Search Stocks

Latest Key Developments (Source: Significant Developments)

CMIC Holdings Co Ltd to acquire JCL Bioassay Corp through Stock Swap
Monday, 17 Nov 2014 01:30am EST 

CMIC Holdings Co Ltd and JCL Bioassay Corp:Announced that CMIC Holdings Co Ltd has decided to fully acquire JCL Bioassay Corp through stock swap, effective March 1, 2015.One JCL Bioassay Corp share can be exchanged to 0.29 share of CMIC Holdings Co Ltd.After the acquisition, JCL Bioassay Corp to delist from JASDAQ market on Feb. 25, 2015.  Full Article

JCL Bioassay Corp revises consolidated mid-year outlook for FY 2015
Thursday, 30 Oct 2014 03:00am EDT 

JCL Bioassay Corp:Says the company lowered the consolidated mid-year outlook for revenue to 1,004 million yen from 1,114 million yen for FY ending March 2015.Operating profit forecast decreased to 7 million yen from 59 million yen.Ordinary profit forecast increased to 87 million yen from 37 million yen.Net profit forecast increased to 39 million yen from 13 million yen.Earnings per share increased to 9.46 yen from 3.30 yen.Comments the decreased income, test facility maintenance costs and exchange gain are the main reasons for the forecast.  Full Article

JCL Bioassay Corp announces changes of auditor
Friday, 16 May 2014 03:00am EDT 

JCL Bioassay Corp:Appoints Ernst & Young ShinNihon LLC as new auditor to replace Deloitte Touche Tohmatsu.Effective June 24.  Full Article

JCL Bioassay revises full-year consolidated outlook for FY 2014
Thursday, 1 May 2014 03:00am EDT 

JCL Bioassay Corp:Full-year consolidated outlook for revenue of 2,207 mln yen lowered from 2,376 mln yen, for fiscal year ended March 31, 2014.Full-year operating profit outlook of 84 mln yen raised from 20 mln yen.Full-year ordinary profit outlook of 172 mln yen raised from 30 mln yen.Full-year net profit (loss) outlook of 62 mln yen raised from (51 mln) yen.Full-year earnings (loss) per share outlook of 18.08 yen raised from (14.83) yen.Revenue outlook lowered due to decreased revenue from domestic bio analysis business and postponed trial of subsidiary, and profit outlook raised due to expense reduction, depreciation of yen and extraordinary profit on endowment insurance contract cancellation.  Full Article

JCL Bioassay expects extraordinary profit for FY 2014
Monday, 31 Mar 2014 03:00am EDT 

JCL Bioassay Corp:Sees extraordinary profit of about 25 mln yen for cancellation of endowment insurance contract, for fiscal year ending March 2014.  Full Article

JCL Bioassay completes private placement
Sunday, 16 Mar 2014 10:00pm EDT 

JCL Bioassay Corp:Completed the private placement of 700,000 shares at 474 yen per share (331,800,000 yen in total), to CMIC Holdings Co Ltd on March 17.  Full Article

JCL Bioassay Corp announces capital and business alliance CMIC Holdings Co Ltd
Thursday, 27 Feb 2014 02:00am EST 

JCL Bioassay Corp:Jointly announces with CMIC Holdings Co Ltd for a capital and business alliance that JCL will issue 700,000 shares at 474 yen per share (331,800,000 yen in total) to CMIC, on March 17.The two companies will also form a business alliance based on a former business alliance to obtain more contract opportunities.CMIC will increase stake in JCL from 4.77 pct to 20.76 pct and become top shareholder, on March 17.  Full Article

JCL Bioassay Corp lowers full-year consolidated outlook for FY 2014
Tuesday, 3 Dec 2013 02:30am EST 

JCL Bioassay Corp:Sees lowered full-year consolidated outlook for fiscal year ending Mar. 31, 2014.Sees full-year revenue of 2,376 million yen lowered from 2,618 million yen.Sees full-year operating profit of 20 million yen lowered from 230 million yen.Sees full-year ordinary profit of 30 million yen lowered from 195 million yen.Sees full-year net profit (loss) of (51 million) yen lowered from 86 million yen.Sees full-year earnings (loss) per share of (14.83) yen lowered from 26.02 yen.Says outlook lowered due to decrease in orders for bioanalysis business and high fixed cost.  Full Article

JCL Bioassay Corp Amends Consolidated Mid-year Outlook for FY 2014
Tuesday, 5 Nov 2013 01:30am EST 

JCL Bioassay Corp announced that it has raised its consolidated mid-year outlook for revenue from JPY 880 million to JPY 970 million, ordinary profit from a loss of JPY 46 million to a loss of JPY 23 million, but lowered the outlook for operating profit from a loss of JPY 28 million to a loss of JPY 55 million, net profit from a loss JPY 29 million to a loss of JPY 47 million and earning per share from a loss of JPY 8.99 to a loss of JPY 13.80, for the fiscal year ending March 2014. The positive outlook is due to the increased sales and the cost reduction, and the negative outlook due to the decreased sales in subsidiary.  Full Article

JCL Bioassay Corp Completes Issuance of New Shares to CMIC Holdings Co Ltd
Thursday, 30 May 2013 10:00pm EDT 

JCL Bioassay Corp announced that it has completed to issue 165,300 new shares, at the price of JPY 1,287 per share, or JPY 212,741,100 in total, to CMIC Holdings Co Ltd, through private placement, on May 31, 2013.  Full Article

Search Stocks